Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment

被引:20
作者
Yalcin, Arzu Didem [1 ]
Bisgin, Atil [2 ]
Kargi, Aysegul [3 ]
Gorczynski, Reginald M. [4 ]
机构
[1] Antalya Educ & Training Hosp, Allergy & Clin Immunol Unit, Antalya, Turkey
[2] Akdeniz Univ, Fac Med, Dept Med Genet, TR-07058 Antalya, Turkey
[3] Denizli Educ & Training Hosp, Dept Med Oncol, Denizli, Turkey
[4] Univ Hlth Network, Toronto Hosp, Div Cellular & Mol Biol, Toronto, ON, Canada
来源
MEDICAL SCIENCE MONITOR | 2012年 / 18卷 / 03期
关键词
severe persistent allergic asthma; allergic asthma; soluble TRAIL; omalizumab; RHEUMATOID-ARTHRITIS; APOPTOSIS; RHINITIS; STRAIL; CELLS; EXPRESSION; SURVIVAL; LIGAND; DEATH; FAS;
D O I
10.12659/MSM.882504
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: In this study we compare the Omalizumab treatment modality in the dynamics of cell apoptosis regulating molecules in both severe persistent asthma patients who had no other any allergic disease, newly diagnosed patients with allergic asthma, and healthy volunteers. Material/Methods: Severe persistent allergic asthma patients were subjected to measurement of serum soluble TRAIL (TNF-related apoptosis-inducing ligand) levels during the active disease phase and the stable phase which occurred 4 months after Omalizumab treatment. Serum sTRAIL concentrations were measured by a solid phase sandwich enzyme-linked immunosorbent assay. Concentration levels were compared with those of age- and sex-matched newly diagnosed patients with allergic asthma, and healthy controls. All assays were carried out in duplicate. Total serum IgE levels, antinuclear antibody (ANA), rheumatoid factor (RF), hepatitis markers, C3, C4 and eosinophil levels were evaluated in all patients. Results: ANA, RF, hepatitis markers were negative in all patients. Complement 3 and 4 levels were normal in all patients. Prick tests in all patients were detected in mite and grass allergy. These results correlated with specific IgE. There were no differences between the healthy controls, newly diagnosed allergic asthma patients, and non-treated severe persistent allergic asthma patients during the active phase. Interestingly, the levels in variances of the patients who had the effective omalizumab treatment were significantly lower than the healthy controls, while the mean values were not statistically significant. Conclusions: Our study gives a different perspective on severe persistent allergic asthma and omalizumab treatment efficacy at the cell apoptosis-linked step by the serum sTRAIL levels.
引用
收藏
页码:PI11 / PI15
页数:5
相关论文
共 25 条
[1]   NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL [J].
Aydin, Cigdem ;
Sanlioglu, Ahter D. ;
Bisgin, Atil ;
Yoldas, Burcak ;
Dertsiz, Levent ;
Karacay, Bahri ;
Griffith, Thomas S. ;
Sanlioglu, Salih .
BMC CANCER, 2010, 10
[2]   Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma [J].
Ayres, JG ;
Higgins, B ;
Chilvers, ER ;
Ayre, G ;
Blogg, M ;
Fox, H .
ALLERGY, 2004, 59 (07) :701-708
[3]  
Bebenek M, 2006, MED SCI MONITOR, V12, pCR457
[4]   TRAIL Death Receptor-4, Decoy Receptor-1 and Decoy Receptor-2 Expression on CD8+ T Cells Correlate with the Disease Severity in Patients with Rheumatoid Arthritis [J].
Bisgin, Atil ;
Terzioglu, Ender ;
Aydin, Cigdem ;
Yoldas, Burcak ;
Yazisiz, Veli ;
Balci, Nilufer ;
Bagci, Huseyin ;
Gorczynski, Reginald M. ;
Akdis, Cezmi A. ;
Sanlioglu, Salih .
BMC MUSCULOSKELETAL DISORDERS, 2010, 11
[5]  
Bisgin A, 2009, HUM GENE THER, V20, P1494
[6]  
Bisgin A, 2009, HUM GENE THER, V20, P1417
[7]   Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis [J].
Chervinsky, P ;
Casale, T ;
Townley, R ;
Tripathy, I ;
Hedgecock, S ;
Fowler-Taylor, A ;
Shen, H ;
Fox, H .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2003, 91 (02) :160-167
[8]  
Daneshmandi S, 2009, IRAN RED CRESCENT ME, V11, P301
[9]   Apoptosis: A review of programmed cell death [J].
Elmore, Susan .
TOXICOLOGIC PATHOLOGY, 2007, 35 (04) :495-516
[10]  
Fu JX, 2010, ARCH MED SCI, V6, P496, DOI 10.5114/aoms.2010.14459